Zenlabs Ethica Limited

ZENLABS6

INE546F01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:58 10/06/2024 pm IST			5-day change	1st Jan Change
43.12 ^INR	+1.77%		+5.22%	+4.15%

20/05	Zenlabs Ethica Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
29/01	Zenlabs Ethica Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Zenlabs Ethica Limited Announces Resignation of Tanvi Chhabra from the Post of Company Secretary & Compliance Officer

May 01, 2023 at 12:22 pm IST

Zenlabs Ethica Limited announced took note of resignation of Mrs. Tanvi Chhabra from the post of company secretary & Compliance officer from the close of business hours of April 28, 2023.

Latest news about Zenlabs Ethica Limited

Zenlabs Ethica Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	20/05	CI
Zenlabs Ethica Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	29/01	CI
Zenlabs Ethica Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	06/11	CI
Zenlabs Ethica Limited Announces Resignation of Ashok Gupta as Independent Director of the Company with Immediate Effect from the Close of Business Hours of 18Th October 2023	19/23/19	CI
Hitesh Popatlal Oswal Leaves His Position of Additional Director from Additional Director	30/23/30	CI
Zenlabs Ethica Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	01/23/01	CI
Zenlabs Ethica Appoints CFO	31/23/31	MT
Zenlabs Ethica Limited Announces Executive Changes	28/23/28	CI
Zenlabs Ethica Limited Appoints Askhay Saxena as Company Secretary Cum Compliance Officer	28/23/28	CI
Zenlabs Ethica Limited Announces CFO Changes	28/23/28	CI
Zenlabs Ethica Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	24/23/24	CI
Zenlabs Ethica Limited Announces Resignation of Tanvi Chhabra from the Post of Company Secretary & Compliance Officer	01/23/01	CI
Zenlabs Ethica Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	09/23/09	CI
Zenlabs Ethica Limited Appoints Hitesh Popatlal Oswal as the Additional Director	21/22/21	CI
Zenlabs Ethica Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	18/22/18	CI
Zenlabs Ethica Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	20/22/20	CI
Zenlabs Ethica Limited Declares Interim Dividend, Payable on or Before August 18, 2022	20/22/20	CI
Zenlabs Ethica Limited Announces Appointment of Tanvi Chhabra as Company Secretary and Compliance Officer	30/22/30	CI
Zenlabs Ethica Limited Announces Resignation of Divya Gupta as Company Secretary and Compliance Officer	03/22/03	CI
Zenlabs Ethica Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Zenlabs Ethica Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	30/21/30	CI
Zenlabs Ethica Limited Announces Resignation of Chander Sheel Baweja from the Position of the Independent Director	03/21/03	CI
Zenlabs Ethica Limited Announces Resignation of Directors	03/21/03	CI
Zenlabs Ethica Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	22/21/22	CI
Zenlabs Ethica Limited Appoints Divya Gupta as the Company Secretary and Compliance Officer	10/21/10	CI

Zenlabs Ethica Limited is an India-based marketing company. The Company is engaged in trading in a range of branded drugs, including gastrointestinal tract disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps and anti-bacterial drugs, nutraceuticals, and other. It has approximately five manufacturing units. It operates through three divisions: Zenlabs, Coles Pharma and Mega Star. Zenlabs division provides various products, including Analgesics & Anti-Inflammatory, Skin Preparations, Neurological Disorders, Eye, Ear and Nasal Drops, Anti-Diabetic, Anti-Depressant, Anti-Infective, Anti-Emetic, Steroid & Anabolic Steroid, Anti-Hypertensive Drugs, Anti Allergic, Anti Cold & Cough Syrup, Nutraceuticals, Antacid, Enzymes & Appetite Stimulant, Ayurvedic Preparation, GIT Disorders, Soap, and Other Pharmaceutical Drugs. Coles Pharma division provides various products, including Analgesics & Anti-Inflammatory, Nutraceuticals, Skin Preparations, and other.

Sector

Pharmaceuticals

Calendar

18/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
ZENLABS ETHICA LIMITED	+4.15%	3.3M
MCKESSON CORPORATION	+27.29%	76.29B
CARDINAL HEALTH, INC.	-2.63%	23.99B
SINOPHARM GROUP CO. LTD.	+10.27%	9.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+12.25%	8.67B
HUADONG MEDICINE CO., LTD	-24.34%	7.58B
H. LUNDBECK A/S	+12.94%	5.18B
GALENICA AG	+1.99%	4.16B
EBOS GROUP LIMITED	-7.75%	3.98B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-1.36%	3.63B